loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Sitravatinib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Sitravatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 21,020Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mirati's wait for next lung cancer med ends in phase 3 failure
    Mirati's wait for next lung cancer med ends in phase 3 failure

    25 May 2023

    // Annalee Armstrong FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/miratis-long-wait-next-lung-cancer-med-ends-phase-3-failure

    Annalee Armstrong FIERCE BIOTECH
    25 May 2023
    Share Share
    Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study
    Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study

    24 May 2023

    // PRESS RELEASE

    https://ir.mirati.com/press-releases/press-release-details/2023/Mirati-Therapeutics-Provides-Update-on-the-Phase-3-SAPPHIRE-Study-Evaluating-Sitravatinib-in-Combination-with-OPDIVO/default.aspx

    PRESS RELEASE
    24 May 2023
    Share Share
    Mirati's sitravatinib yet to improve survival at interim review
    Mirati's sitravatinib yet to improve survival at interim review

    02 Dec 2022

    // Nick Paul Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/miratis-sitravatinib-yet-improve-survival-interim-phase-3-cancer-review-pushing-back

    Nick Paul Taylor FIERCEBIOTECH
    02 Dec 2022
    Share Share
    Mirati Therapeutics Presents Ph2 Data On Sitravatinib With Nivolumab
    Mirati Therapeutics Presents Ph2 Data On Sitravatinib With Nivolumab

    18 Sep 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/mirati-therapeutics-presents-phase-2-data-on-sitravatinib-in-combination-with-nivolumab-in-urothelial-cancer-at-esmo-virtual-congress/

    BIOSPACE
    18 Sep 2020
    Share Share
    Mirati's Announces Initial Data In RCC a Sitravatinib In Combination
    Mirati's Announces Initial Data In RCC a Sitravatinib In Combination

    17 Feb 2020

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-initial-data-in-renal-cell-carcinoma-from-ongoing-investigator-sponsored-clinical-trial-of-sitravatinib-in-combination-with-nivolumab-at-the-2020-asco-genitourinary-cancers-syposium-301005654.html

    PR NEWSWIRE
    17 Feb 2020
    Share Share
    Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib
    Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib

    24 Oct 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-presentation-of-interim-phase-2-sitravatinib-data-in-urothelial-carcinoma-and-oral-cavity-squamous-cell-carcinoma-at-the-sitc-34th-annual-meeting-300944341.html

    PR NEWSWIRE
    24 Oct 2019
    Share Share